[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"kaposis-sarcoma\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:kaposis-sarcoma":25},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,46,72],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":17,"targetDuration":4,"studyType":20,"phases":4,"briefSummary":21,"conditions":22,"keywords":27,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":45},"100053304","molecular-characterization-of-viral-associated-tumors-tumors-occurring-in-the-setting-of-hiv-or-other-immune-disorders-and-castleman-disease-100053304",false,"NCT03300830","Molecular Characterization of Viral-associated Tumors, Tumors Occurring in the Setting of HIV or Other Immune Disorders and Castleman Disease","* INCLUSION CRITERIA:\n\nParticipants with one or more of the following:\n\n* HIV or other acquired immunodeficiency and cancer\n* Viral-associated cancer or cancer hypothesized to be caused by a virus\n* HIV-negative participants with cancer that commonly occurs in people with HIV\n\n  --KSHV-associated malignancy or related diseases, such as Multicentric Castleman Disease (MCD)\n* A malignancy hypothesized to be caused by an endogenous retrovirus\n* Idiopathic Castleman disease\n\nCancer diagnoses will be confirmed by the NCI Laboratory of Pathology (LP). A biopsy will be collected if sufficient archival tissue is not available.\n\n* Age \\>=18 years.\n* ECOG performance status \\\u003C=2 (Karnofsky \\>=60%) if biopsy to be performed is solely for the purposes of this protocol. Any ECOG performance status will be allowed if biopsy required for participant care or another NIH protocol that allows lower performance status or if enrollment on this protocol is only for the purposes of studying tissue that has already been collected.\n* Participants must have signed or be willing to sign an IRB-approved informed consent document that permits the use of the tumor and other samples for genomic-based molecular characterization projects. Telephone consent for use of archival tissue or tissue collected on another protocol or standard participant care will be permitted.\n* Co-enrollment on other HAMB, NCI, or NIH protocols is allowed\n\nEXCLUSION CRITERIA:\n\n* Inability to provide informed consent.\n* Pregnancy: Pregnant women will not be allowed to participate in this study because there is not a potential benefit.","ALL","18 Years",{"count":18,"type":19},280,"ESTIMATED","OBSERVATIONAL","Background:\n\nA person s genome is the collection of all their genes. A gene instructs individual cells to make proteins. Proteins are involved in all of our body s chemical processes. Genome sequencing allows researchers to find variations in genes. Some of these are normal and are not known to cause disease. Some variants are known to cause or affect diseases like cancer. Researchers want to study genetic variants in people with cancer who also have an immunologic disease like HIV.\n\nObjective:\n\nTo study the biology of cancer in order to improve ways to prevent, detect, and treat it.\n\nEligibility:\n\nAdults at least 18 years old with certain cancers and\u002For immunodeficiencies\n\nDesign:\n\nParticipants will be screened with medical history, physical exam, and lab tests.\n\nParticipants will give samples of one or more tissue type.\n\nThey may give blood or urine samples.\n\nResearchers may get samples of tissue when participants have surgery or when the participants are on other protocols in the NCI.\n\nParticipants may have a procedure to have tissue samples removed.\n\nResearchers may collect data from participant medical records.\n\nResearchers will compare the genes in a participant s cancer tissue to their normal tissue. They may use the tissue cells to grow new cells in a lab.\n\nParticipants may be contacted about the results.\n\nThe samples will be stored for future research. No personal data will be kept with them.\n\n...",[23,24,25,26],"Human Immunodeficiency Virus","Castleman's Disease","Kaposi's Sarcoma","Viral-Associated Cancer",[28,26,29,30,31,32],"Immunodeficiency","Kaposi Sarcoma Herpes Virus","Idiopathic Castleman Disease","Endogenous Retroviruses","Natural History","RECRUITING","2026-07-10",{"date":36,"type":37},"2026-07-13","ACTUAL",{"date":39,"type":37},"2017-12-20",{"date":41,"type":19},"2037-06-25",{"name":43,"class":44},"National Cancer Institute (NCI)","NIH",1,{"id":47,"slug":48,"hasResults":11,"nctId":49,"briefTitle":50,"officialTitle":51,"acronym":4,"eligibilityCriteria":52,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":53,"targetDuration":4,"studyType":20,"phases":4,"briefSummary":55,"conditions":56,"keywords":61,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":66,"lastUpdatePostDateStruct":67,"startDateStruct":69,"completionDateStruct":4,"leadSponsor":71,"locationsCount":45},"100058758","specimen-collections-from-participants-with-hiv-infection-kshv-infection-viral-related-pre-malignant-lesions-and-cancer-100058758","NCT00006518","Specimen Collections From Participants With HIV Infection, KSHV Infection, Viral-Related Pre-malignant Lesions and Cancer","Collection of Blood, Bone Marrow, Tumor, or Tissue Samples From Patients With HIV Infection, KSHV Infection, Viral-Related Pre-Malignant Lesions, and\u002For Cancer","* INCLUSION CRITERIA:\n* Age 18 years or older.\n* ECOG performance status less than or equal to 3\n\nAt least one of the following:\n\n* Exposure risk to HIV, KSHV, or HPV\n* HIV seropositive\n* KSHV seropositive\n* EBV seropositive\n* HTLV-1 seropositive\n\nNOTE: infection with HIV, KSHV, EBV, and HTLV-1 are life-long, so if participants have previously been seropositive or have had a disease associated with KSHV (KS, primary effusion lymphoma \\[PEL\\], or KSHV-multicentric Castleman s disease \\[MCD\\]), this is sufficient to meet this criterion for eligibility.\n\n* Malignancy, MCD, or skin lesions with appearance of KS\n* Cervical or anal intraepithelial lesion\n* Ability of participant to understand and the willingness to sign a written informed consent document.\n\nEXCLUSION CRITERIA:\n\nNone",{"count":54,"type":19},1029,"BACKGROUND:\n\n* A number of important scientific advances can be made through the study of blood, bone marrow, tumor, or other tissue samples from patients with HIV infection, infection with Kaposi s sarcoma associated herpesvirus (KSHV), infection with other oncogenic viruses, or cancer.\n* This protocol provides a mechanism to affect a variety of such studies.\n\nOBJECTIVES:\n\n-Acquisition of serum, circulating cells, bone marrow, and tumor or normal tissue samples from participants with HIV infection, KSHV infection, or with cancer.\n\nELIGIBILITY:\n\n-Eligibility criteria include age 18 years or older and at least one of the following: Exposure risk to HIV, KSHV, or HPV; HIV seropositive; KSHV seropositive; EBV seropositive; HTLV-1 seropositive; malignancy, Castleman s disease, or skin lesions with appearance of Kaposi s sarcoma; or cervical or anal intraepithelial lesion.\n\nDESIGN:\n\n* Up to 999 subjects will be enrolled in this study.\n* Blood samples may be collected at the initial visit, and at follow-up visits.\n* Other fluids\u002Fexcretions may be collected (such as urine, saliva, semen, and stool).\n* Tumor samples may be obtained by fine needle aspirate, by removal of pleural or peritoneal fluid, by skin punch biopsy, or by excisional biopsy, providing the tumor is accessible with minimal risk to the participants.\n* Specific risks will be described in a separate consent to be obtained at the time of the biopsy.\n* Samples will be studied in the HIV and AIDS Malignancy Branch, CCR, NCI; laboratories in NCI-Frederick; or those of collaborating investigators.",[57,25,58,59,60],"HIV","Lymphomas","Multicentric Castleman's Disease","Primary Effusion Lymphoma",[62,63,57,64,65,32],"Tumor","Viruses","KSHV","AIDS","2026-06-27",{"date":68,"type":37},"2026-06-30",{"date":70,"type":37},"2000-12-06",{"name":43,"class":44},{"id":73,"slug":4,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":74,"targetDuration":4,"studyType":20,"phases":4,"briefSummary":21,"conditions":75,"keywords":76,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":77,"lastUpdatePostDateStruct":78,"startDateStruct":80,"completionDateStruct":81,"leadSponsor":82,"locationsCount":45},"100308862",{"count":18,"type":19},[23,24,25,26],[28,26,29,30,31,32],"2026-06-23",{"date":79,"type":37},"2026-06-24",{"date":39,"type":37},{"date":41,"type":19},{"name":43,"class":44}]